Gene editing Archives

In Depth 31 Jan 2018

Why Does Europe Lag Behind the US and China in the Gene Editing Race?

America and China lead the development of new gene editing technologies, producing GMOs and bringing CRISPR-based therapies into the clinic. Could this render European biotechs in this area obsolete? Gene editing technologies have revolutionized genetics and mark a new generation in biomedical and agricultural sciences. There are endless applications for the technology, including gene therapies for […]

January 31, 2018 - 6 minutesmins - By Ekaterina Perets

News and Trends 22 Jan 2018

European Court Supports the Softening of CRISPR Gene Editing Rules

The tough regulations that apply to genetically modified organisms may no longer affect plants and animals created using CRISPR gene editing technology. The European Court of Justice has ruled that crops and drugs developed using precise gene-editing techniques like CRISPR/Cas9 may not need to be regulated as strictly as genetically modified organisms (GMOs). So far, […]

January 22, 2018 - 3 minutesmins - By Alex Dale

News and Trends 19 Dec 2017

Giving Molecular Combing the Golden Coat It Deserves

The novel spin given to some traditional and established technologies can be astounding. They might have been around for decades, applied in the same way over and over again, and yet, at some point, somebody comes along, observes it in a new light and gives it a brand new polish. One such technology is called […]

December 19, 2017 - 5 minutesmins - By External Contributor

CRISPR Therapeutics clinical trials CRISPR Cas9

News and Trends 13 Dec 2017

CRISPR Therapeutics Plans First CRISPR/Cas9 Clinical Trial in Europe for 2018

CRISPR Therapeutics and Vertex Pharmaceuticals are taking action to start a first clinical trial with CRISPR/Cas9 in Europe in 2018. The blood disorder β-thalassemia could soon be the first human disease to be treated using CRISPR/Cas9 technology in Europe. CRISPR Therapeutics and its partner Vertex Pharmaceuticals have announced the first candidate from their collaboration that will go […]

December 13, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 26 Oct 2017

New and Improved CRISPR: More Precise Genome Editing Now Possible

US Scientists have developed a new form of CRISPR, base editing, which can repair tiny genome segments, smaller than a single gene. Here at Labiotech, we focus on European biotech, but this was too big to miss: Researchers based at MIT and Harvard have described a new way of editing DNA and RNA — base […]

October 26, 2017 - 3 minutesmins - By Alex Dale

News and Trends 17 Jul 2017

A Brand New Outlook on Induced Pluripotent Stem Cells

In an exclusive interview with Dr David Hallett, we discover why iPS cells are the perfect replacement for human embryonic stem cells, what is so unique about them and the challenges researchers face in the field! Talk of using human stem cells to better understand and even cure diseases has been around for a few decades. […]

July 17, 2017 - 8 minutesmins - By External Contributor

News and Trends 7 Jul 2017

Better than CRISPR? New Genetic Analysis Method ropes in Long-Read DNA Cloning

After CRISPR, there’s a new genetic technique with a tongue-in-cheek name in town: LASSO cloning. Researchers from four institutions, including the US-based John Hopkins, Rutgers and Harvard, and the University of Trento in Italy, have developed a new technology to study large chunks of DNA and their function. The work behind it was recently published in Nature Biomedical […]

July 7, 2017 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 3 Jul 2017

From Rockets to DNA – From SpaceX to CRISPR

With CRISPR being one of the most significant discoveries in genome engineering history, many scientists are now turning towards it as a basic foundation of their research. In response, companies are developing new technologies and products designed to help these very scientists become more effective in their research. One such company is Silicon Valley entity […]

July 3, 2017 - 6 minutesmins - By External Contributor

servier transgene car t cells viral vector

News and Trends 29 Jun 2017

Servier Recruits Viral Vector Expert to Step Up its CAR-T Technology

Transgene will help Servier develop new methods based on viral vectors to improve the precision of genetic modifications and the production of CAR-T cells. The French pharma Servier decided to enter the promising CAR-T field in 2015, when it acquired the rights to UCART19 from Cellectis. The therapy, currently in Phase I, has already saved two babies […]

June 29, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 28 Jun 2017

UPDATE: The First Off-the-Shelf CAR-T Cancer Therapy has Entered the Clinic

Update (28/06/2017): Cellectis has announced the first administration of UCART123 in its Phase I trial in Acute Myeloid Leukemia. Update (07/02/2017): the FDA has granted Cellectis IND approval to start clinical trials with UCART123. Original publication 04/01/2017 Cellectis is preparing to start the first clinical trial ever using an allogeneic CAR-T therapy that could reduce […]

June 28, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

In Depth 13 Jun 2017

Will Gene Editing Bypass the GMO Struggle or Worsen Public Distrust?

In the US, the first CRISPR-edited crops were able to bypass GMO regulations, but Europe’s plant scientists are still awaiting the final go ahead. In April 2016, the US Department of Agriculture (USDA) gave the green light to the first CRISPR-edited crops, a mushroom that has been engineered to resist browning and a waxy corn from […]

June 13, 2017 - 6 minutesmins - By Melanie De Almeida

David Sourdive Cellectis interview off the shelf cell therapy 1

Interview 16 Mar 2017

“In the Coming Decade, Off-the-Shelf Cell Therapy will Become a Reality”

David Sourdive, co-founder of Cellectis, discusses his pioneering work developing off-the-shelf CAR-T for cancer and the future directions of cell therapy. Last week I had the opportunity to attend the World ADOPT Summit and hear from some of the world leaders in cell therapy. There I met David Sourdive, co-founder and EVP Technical Operations at Cellectis, […]

March 16, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us